Pyxis Oncology, Inc. / Fundamentals
Income statement
- Net revenue
€5.34M - Cost of goods sold
€1.46M - Gross profit
€3.88M - SG&A expenses
€19.22M - R&D expenses
€57.54M - EBITDA
-€71.82M - D&A
€1.56M - EBIT
-€91.37M - Interest expenses
€0.00 - EBT
-€84.23M - Tax expenses
-€1.61M - Net income
-€82.61M
Cash flow statement
- Net deferred tax
-€1.86M - Non-cash items
€10.59M - Changes in working capital
€838.27K - Operating cash flow
-€63.28M - Capex
€0.00 - Other investing cash flow
€175.60M - Net investing cash flow
€49.57M - Total cash dividends paid
€0.00 - Issuance of common stock
€1.36M - Debt repayment
€0.00 - Other financing cash flow
€114.11K - Net financing cash flow
€1.47M - Foreign exchange effects
€0.00 - Net change in cash
-€12.30M - Cash at end of period
€10.47M - Free cash flow
-€63.28M
Balance sheet
- Cash and cash equivalents
€9.21M - Cash and short-term investments
€76.31M - Total receivables
€2.57M - Inventory
€0.00 - Other current assets
€6.87M - Total current assets
€85.76M - Property, plant & equipment
€17.82M - Goodwill
€0.00 - Intangible assets
€2.13M - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€19.96M - Total assets
€105.72M - Accounts payable
€8.08M - Short-term debt
€1.35M - Other current liabilities
€5.75M - Total current liabilities
€15.17M - Long-term debt
€15.35M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€15.35M - Total liabilities
€30.52M - Common stock
€53.20K - Retained earnings
-€345.83M - Other equity
-€4.29K - Total equity
€75.20M - Total liabilities and shareholders' equity
€105.72M
Company information
- Market capitalization
€58.12M - Employees
44 - Enterprise Value
€86.38M
Company ratios
- Gross margin
-
72.7% Much better than peer group: -19.1% - EBITDA margin
-
-1,345.3% Much better than peer group: -14,699.0% - EBIT margin
-
-1,711.5% Much better than peer group: -24,789.1% - EBT margin
-
-1,577.7% Much better than peer group: -239,810.1% - Net margin
-
-1,547.5% Much better than peer group: -238,148.6% - ROE
-
-109.9% Much better than peer group: -1,261.1% - ROA
-
-78.1% Much better than peer group: -870.9% - Asset turnover
-
5.0% Even with peer group: 5.1% - FCF margin
-
-1,185.4% Much better than peer group: -279,682.3% - FCF yield
-108.9% - Efficiency ratio
1,445.3% - Net sales per employee
-
€121.33K - Net income per employee
-
-€1.88M